Warning: mkdir(): Permission denied in /data/Websites/newwiki-mpm/fuel/core/classes/log.php on line 122

Warning!

ErrorException [ Warning ]: mkdir(): Permission denied

COREPATH/classes/log.php @ line 122:

121:	
122:	mkdir($filepath, \Config::get('file.chmod.folders', 0777), true);
123:	umask($old);
IRS2 - Wiki-MPM

Search Results for: IRS2

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel CDKL1 cyclin dependent kinase like 1
  • Fostamatinib
Novel CUL4A cullin 4A
  • Recognition of DNA damage by PCNA-containing replication complex
  • DNA Damage Recognition in GG-NER
  • Formation of Incision Complex in GG-NER
  • Dual Incision in GG-NER
  • Formation of TC-NER Pre-Incision Complex
  • Transcription-Coupled Nucleotide Excision Repair (TC-NER)
  • Dual incision in TC-NER
  • Gap-filling DNA repair synthesis and ligation in TC-NER
  • Neddylation
Novel EDEM1 ER degradation enhancing alpha-mannosidase like protein 1
  • XBP1(S) activates chaperone genes
  • ER Quality Control Compartment (ERQC)
Novel LAMP1 lysosomal associated membrane protein 1
  • Neutrophil degranulation
Novel MPO myeloperoxidase
  • Neutrophil degranulation
  • Events associated with phagocytolytic activity of PMN cells
  • Mesalazine
  • Cefdinir
  • Levocarnitine
  • Melatonin
  • Nomifensine
  • Other phagocyte defects, including the following eight diseases: Chediak-Higashi syndrome; Griscelli syndrome, type 1 (GS1); Griscelli syndrome, type 2 (GS2); Griscelli syndrome, type 3 (GS3); beta-actin deficiency; Neutrophil-specific granule deficiency; Myeloperoxidase deficiency; Glucose 6-phosphate dehydrogenase deficiency; Shwachman syndrome
Novel NRAS NRAS proto-oncogene, GTPase
  • SOS-mediated signalling
  • Activation of RAS in B cells
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB4 signaling
  • Signaling by SCF-KIT
  • Signalling to RAS
  • p38MAPK events
  • p38MAPK events
  • GRB2 events in EGFR signaling
  • SHC1 events in EGFR signaling
  • Downstream signal transduction
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • Tie2 Signaling
  • EGFR Transactivation by Gastrin
  • DAP12 signaling
  • SHC-related events triggered by IGF1R
  • FCERI mediated MAPK activation
  • NCAM signaling for neurite out-growth
  • Ras activation upon Ca2+ influx through NMDA receptor
  • VEGFR2 mediated cell proliferation
  • CD209 (DC-SIGN) signaling
  • Constitutive Signaling by EGFRvIII
  • SHC-mediated cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Regulation of RAS by GAPs
  • RAF activation
  • RAF/MAP kinase cascade
  • MAP2K and MAPK activation
  • Negative regulation of MAPK pathway
  • Neutrophil degranulation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • RAS signaling downstream of NF1 loss-of-function variants
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Insulin receptor signalling cascade
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAS signaling
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • Activated NTRK2 signals through RAS
  • Erythropoietin activates RAS
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK3 signals through RAS
  • FLT3 Signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Estrogen-stimulated signaling through PRKCZ
  • RAS processing
  • RAS GTPase cycle mutants
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
  • Oral cancer
  • Acute myeloid leukemia (AML)
  • Multiple myeloma
  • Adrenal carcinoma
  • Thyroid cancer
  • Hepatocellular carcinoma
  • Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
  • Malignant melanoma
Novel PROZ protein Z, vitamin K dependent plasma glycoprotein
  • Gamma-carboxylation of protein precursors
  • Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus
  • Removal of aminoterminal propeptides from gamma-carboxylated proteins
Novel PTPRR protein tyrosine phosphatase receptor type R
Novel RAP2A RAP2A, member of RAS oncogene family
  • Guanosine-5'-Triphosphate
  • Guanosine-5'-Diphosphate
Novel SLC35B1 solute carrier family 35 member B1
ATP2A1 ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1
  • Pre-NOTCH Processing in Golgi
  • Reduction of cytosolic Ca++ levels
  • Ion homeostasis
  • Ion transport by P-type ATPases
  • Enflurane
  • Desflurane
  • Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate
  • Tetrafluoroaluminate Ion
  • 2,5-di-tert-butylhydroquinone
  • (6AR,11AS,11BR)-10-ACETYL-9-HYDROXY-7,7-DIMETHYL-2,6,6A,7,11A,11B-HEXAHYDRO-11H-PYRROLO[1',2':2,3]ISOINDOLO[4,5,6-CD]INDOL-11-ONE
  • Brody myopathy
ATP2A2 ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2
  • Pre-NOTCH Processing in Golgi
  • Reduction of cytosolic Ca++ levels
  • Ion homeostasis
  • Ion transport by P-type ATPases
  • Desflurane
  • Istaroxime
  • Acrokeratosis verruciformis
  • Darier disease; Dyskeratosis follicularis
BCL2L1 BCL2 like 1
  • BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
  • Interleukin-4 and Interleukin-13 signaling
  • The NLRP1 inflammasome
  • RAS processing
  • STAT5 activation downstream of FLT3 ITD mutants
  • 4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID
  • Isosorbide
  • Gossypol
CRK CRK proto-oncogene, adaptor protein
  • ARMS-mediated activation
  • ARMS-mediated activation
  • Downstream signal transduction
  • Regulation of actin dynamics for phagocytic cup formation
  • p130Cas linkage to MAPK signaling for integrins
  • VEGFA-VEGFR2 Pathway
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • Regulation of signaling by CBL
  • FCGR3A-mediated phagocytosis
EPOR erythropoietin receptor
  • Signaling by Erythropoietin
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phospholipase C gamma (PLCG)
  • Erythropoietin activates STAT5
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Darbepoetin alfa
  • Erythropoietin
  • Dibromotyrosine
  • Peginesatide
  • Methoxy polyethylene glycol-epoetin beta
  • Congenital polycythemia; Familial erythrocytosis (ECYT)
FES FES proto-oncogene, tyrosine kinase
  • Signaling by SCF-KIT
  • Sema3A PAK dependent Axon repulsion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • Fostamatinib
GRB2 growth factor receptor bound protein 2
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
IGF1R insulin like growth factor 1 receptor
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • IRS-related events triggered by IGF1R
  • SHC-related events triggered by IGF1R
  • Extra-nuclear estrogen signaling
  • Insulin human
  • Insulin lispro
  • Insulin glargine
  • Insulin pork
  • Mecasermin
  • Insulin aspart
  • Insulin detemir
  • Insulin glulisine
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • ATL1101
  • XL228
  • rhIGFBP-3
  • Linsitinib
  • Teprotumumab
  • (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione
  • 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE
  • Somatrem
  • Insulin degludec
  • Cixutumumab
  • Brigatinib
  • Mecasermin rinfabate
  • Malignant pleural mesothelioma
  • Synovial sarcoma
IL4R interleukin 4 receptor
  • Interleukin-4 and Interleukin-13 signaling
  • AER001
  • Dupilumab
  • Asthma
INSR insulin receptor
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • IRS activation
  • Signal attenuation
  • Insulin receptor signalling cascade
  • Signaling by Insulin receptor
  • Insulin receptor recycling
  • Insulin human
  • Insulin lispro
  • Insulin glargine
  • Insulin pork
  • Mecasermin
  • Insulin aspart
  • Insulin detemir
  • Insulin glulisine
  • Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate
  • NN344
  • AT1391
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
  • Chromic chloride
  • Insulin degludec
  • Fostamatinib
  • Brigatinib
  • Mecasermin rinfabate
  • Rabson-Mendenhall syndrome
  • Leprechaunism ; Donohue syndrome

Page 1 out of 3 pages